(Reuters) - NEW YORK, April 22 - Britain's AstraZeneca Plc is near a deal to buy U.S. biotechnology company MedImmune Inc. in a transaction that could be worth more than $13 billion, the Wall Street Journal reported on its Web site on Sunday.
The deal could be announced on Monday morning, the paper reported, citing unidentified sources.
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment